Baxter's revenue has held near $2.7B to $3.0B per quarter over the last ten quarters, with recent year-over-year growth of roughly 3% to 8% suggesting a modest top-line recovery that has not yet accelerated.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has held roughly flat near $2.7B to $3.0B while gross margin swung between 19.4% and 35.3% and operating margin ranged from -24.5% to 7.6%, indicating weak cost absorption against SG&A of roughly $700M to $760M per quarter.
Multiple bullish theses on Baxter International Inc. highlight its potential as a good stock to buy, supported by value investing perspectives.
Baxter's long-standing history since 1931 and its reputation in medical solutions contribute to its enduring market presence.
The company attracts skilled professionals across various fields, enhancing innovation and operational efficiency.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $0.58+12.0% vs $0.52 | $3.0B+2.3% vs $2.9B |
Q3 2026 Jul 30, 2026 | $0.56+52.8% vs $0.37 | $3.0B+5.9% vs $2.8B |
Q2 2026 Apr 30, 2026 | $0.36+15.8% vs $0.31 | $2.7B+3.3% vs $2.6B |
Q1 2026 Feb 12, 2026 | $0.44-17.0% vs $0.53 | $3.0B+5.3% vs $2.8B |
Baxter International Inc. BAX is scheduled to release third-quarter 2026 results on Oct. 29, before the opening bell. In the last reported quarter, the company's earnings beat the Zacks Consensus Estimate by 55.6%.
Cohen Klingenstein LLC acquired a new position in shares of Baxter International Inc. (NYSE: BAX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 20,728 shares of the medical instruments supplier's stock, valued at approximately $497,000. Several other institutional investors and
Baxter International is rated Hold, with a $25 target price and limited 2.6% upside, reflecting muted near-term margin recovery. Revenue growth is supported by Advanced Surgery and compounding, but infusion solutions face structural headwinds, and Novum IQ LVP supply issues persist. Margins lag revenue growth; cost reductions and inventory normalization may help, but transition expenses and debt reduction remain priorities through 2027.
Omnicell (NASDAQ: OMCL - Get Free Report) and Baxter International (NYSE: BAX - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings. Analyst Recommendations This is a breakdown of recent ratings
Benchmark BAX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Baxter International Inc. (BAX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $25.79 | $13.32B | -14.74 | 5.72% | -8.51% | -14.58% | 2.63% | |
| $211.88 | $58.38B | 36.34 | 8.23% | 4.52% | 3.79% | 1.97% | |
| $42.75 | $63.54B | 22.04 | 19.87% | 16.56% | 13.74% | — | |
| $102.14 | $58.81B | 55.81 | 11.55% | 15.43% | 9.66% | — | |
| $1.88 | $7.68M | -0.32 | 814.07% | -795.5% | -162.75% | — | |
| $86.05 | $9.8B | 26.32 | 4.03% | 3.07% | 8.83% | — |
Baxter International Inc. (BAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Baxter International Inc. (BAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Jul 30, 2026·SEC
Jul 14, 2026·SEC
Get notified when BAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Baxter International Inc. (BAX) stock FAQ — growth, dividends, profitability & financials explained
Baxter International Inc. (BAX) reported $11.61B in revenue over the trailing twelve months. Revenue was $11.24B in fiscal year 2025. That is 107% more than the $5.44B of fiscal year 1996.
Baxter International Inc. (BAX) grew revenue by 5.7% in fiscal year 2025, compared with the prior fiscal year.
No. Baxter International Inc. (BAX) reported a net loss of $723.0M over the trailing twelve months.
Yes. Baxter International Inc. (BAX) pays a dividend that yields 2.63% at the current price, a moderate yield.
Baxter International Inc. (BAX) had a return on equity (ROE) of -14.6% in fiscal year 2025. A negative ROE means the company lost money over the period.
Baxter International Inc. (BAX) generated $1.00B in free cash flow over the trailing twelve months.
